Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver diseaseZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Peio Aristu-Zabalza et al.|Journal of Hepatology|2020Cited by 163
Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021Xiaodong Zhou, Mohit Kehar, Mehmet Kızılkaya et al.|Clinical Nutrition|2024Cited by 44
The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for CancerAlbert Gibert‐Ramos, Anabel Fernández‐Iglesias, David Sanfeliu-Redondo et al.|Cancers|2021Cited by 39
Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as NutraceuticalZoe Boyer‐Díaz, Jordi Gracia‐Sancho, Paloma Morata et al.|Nutrients|2020Cited by 26
New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human DiseaseRaquel Maeso‐Díaz, Jordi Gracia‐Sancho|Cells|2019Cited by 25